However, the objective clinical responses of immune checkpoint inhibitors lead by anti-PD-1 therapy is only 30% to 40%.2BRAF and MEK inhibitors represent the standard first-line therapy for BRAF-mutated advanced melanoma, but BRAF gene mutation rate in Chinese population is less than 26%.3 Clinically, some patients have developed resistance to BRAF and MEK inhibitors, or have experienced serious drug-related adverse reactions.4, 5 Therefore, chemotherapy remains the main treatment for patients experiencing primary or acquired resistance to immune checkpoint inhibitors or BRAF-MEK inhibitor. The gene discussed is BRAF; the disease is melanoma.